Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
Neurology. 2018 May 15;90(20):e1805-e1814.
Objective: To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS).
Methods: Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatumumab 60 mg every 4 weeks, or placebo for a 24-week treatment period, with a primary endpoint of cumulative number of new gadolinium-enhancing lesions (per brain MRI) at week 12. Relapses and safety/tolerability were assessed, and CD19+ peripheral blood B-lymphocyte counts measured. Safety monitoring continued weeks 24 to 48 with subsequent individualized follow-up evaluating B-cell repletion.
Results: The cumulative number of new lesions was reduced by 65% for all ofatumumab dose groups vs placebo (p < 0.001). Post hoc analysis (excluding weeks 1-4) estimated a ≥90% lesion reduction vs placebo (week 12) for all cumulative ofatumumab doses ≥30 mg/12 wk. Dose-dependent CD19 B-cell depletion was observed. Notably, complete depletion was not necessary for a robust treatment effect. The most common adverse event was injection-related reactions (52% ofatumumab, 15% placebo), mild to moderate severity in 97%, most commonly associated with the first dose and diminishing on subsequent dosing.
Conclusion: Imaging showed that all subcutaneous ofatumumab doses demonstrated efficacy (most robust: cumulative doses ≥30 mg/12 wk), with a safety profile consistent with existing ofatumumab data. This treatment effect also occurred with dosage regimens that only partially depleted circulating B cells.
Classification of evidence: This study provides Class I evidence that for patients with RMS, ofatumumab decreases the number of new MRI gadolinium-enhancing lesions 12 weeks after treatment initiation.
Trial registration: ClinicalTrials.gov NCT01457924.
Free full text.
Ofatumumab Phase IIb Trial, MIRROR Study
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1381 Views
-
Last post by frodo
-
- 0 Replies
- 1025 Views
-
Last post by frodo
-
- 0 Replies
- 1298 Views
-
Last post by frodo
-
- 0 Replies
- 1714 Views
-
Last post by NHE
-
- 1 Replies
- 3144 Views
-
Last post by Tif
-
- 2 Replies
- 4342 Views
-
Last post by DIM
-
- 0 Replies
- 2497 Views
-
Last post by NHE
-
- 0 Replies
- 2500 Views
-
Last post by NHE
-
- 0 Replies
- 13091 Views
-
Last post by NHE